Clinical Trial Update: Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Lymphoma | Phase 1, Phase 2 | Status: WITHDRAWN